Skip to main content

Table 3 Mean data for efficacy and health-related quality of life scores

From: Maintenance of Remission with Etanercept–DMARD Combination Therapy Compared with DMARDs Alone in African and Middle Eastern Patients with Active Rheumatoid Arthritis

Parameter Period 1 Period 2 Period 1 Period 2
ETN50 + MTX ± nbDMARDs (N = 34) PBO + MTX ± nbDMARDs (N = 27)
At baseline (N = 64) At week 24 At week 52 At baseline (N = 64) At week 24 At week 52
DAS28-ESR 6.0 (0.9) 2.5 (0.5) 3.3 (1.3) 5.8 (1.1) 2.5 (0.4) 4.0 (1.3)
DAS28-CRP 5.8 (0.8) 2.5 (0.7) 3.0 (1.4) 5.4 (1.1) 2.4 (0.6) 3.5 (1.2)
CDAI 36.0 (9.8) 5.1 (3.7) 10.1 (10.9) 35.0 (12.5) 5.1 (3.2) 14.0 (11.5)
SDAI 40.6 (10.8) 6.3 (4.1) 11.0 (11.7) 36.6 (13.7) 6.0 (3.6) 15.3 (11.6)
ESR 38.5 (27.1) 14.5 (12.0) 25.5 (17.3) 29.2 (14.1) 15.1 (10.7) 27.7 (15.3)
CRP 45.7 (62.1) 12.1 (14.1) 10.0 (15.0) 16.2 (21.8) 9.2 (11.6) 12.4 (14.2)
28TJC 12.6 (5.7) 1.3 (1.4) 2.7 (3.8) 12.7 (6.8) 1.1 (1.0) 4.6 (5.7)
28SJC 9.5 (5.1) 1.1 (2.3) 2.8 (4.3) 9.4 (4.7) 0.7 (1.4) 2.4 (3.7)
PGA 6.9 (1.1) 1.4 (0.8) 2.1 (2.0) 6.6 (1.9) 1.7 (1.3) 3.5 (2.2)
HAQ-DI 1.6 (0.5) 0.3 (0.3) 0.4 (0.5) 1.3 (0.8) 0.4 (0.5) 0.6 (0.7)
PtGA 7.0 (1.4) 1.4 (0.9) 2.5 (2.2) 6.3 (2.1) 1.6 (1.2) 3.6 (2.3)
Patient general health 63.6 (20.1) 11.0 (5.6) 22.1 (24.8) 55.0 (24.9) 13.2 (8.8) 34.3 (25.4)
Pain VAS 68.4 (15.4) 9.9 (5.6) 21.6 (24.5) 63.1 (22.8) 12.1 (8.7) 32.5 (22.2)
EQ-5D Health State 43.7 (17.6) 87.4 (6.7) 80.6 (18.7) 43.6 (25.4) 86.8 (9.4) 72.2 (19.8)
EQ-5D Utility Score 0.3 (0.4) 0.9 (0.1) 0.8 (0.2) 0.4 (0.4) 0.8 (0.2) 0.7 (0.2)
WPAI: % time missed due to health 10.4 (12.3) 3.6 (9.1) 1.0 (2.6) 7.5 (12.9) 10.0 (16.5) 2.4 (4.1)
WPAI: % impairment while working due to health 45.5 (25.1) 13.0 (19.5) 6.7 (12.1) 40.0 (19.5) 15.0 (21.2) 16.7 (15.3)
WPAI: % overall work impairment due to health 4.9 (4.9) 2.2 (4.6) 1.1 (2.3) 4.0 (4.2) 6.5 (10.4) 2.0 (2.8)
WPAI: % activity impairment due to health 60.5 (17.6) 13.6 (12.9) 9.2 (13.8) 60.0 (22.0) 16.4 (16.4) 13.8 (17.7)
  1. Data are presented as the mean with the SD in parenthesis
  2. EQ-5D Euro-Qol 5D, nbDMARD non-biological DMARD, WPAI work productivity activity impairment